Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Fleming, Viktor [VerfasserIn]   i
 Hu, Xiaoying [VerfasserIn]   i
 Weber, Rebekka [VerfasserIn]   i
 Groth, Christopher [VerfasserIn]   i
 Altevogt, Peter [VerfasserIn]   i
 Utikal, Jochen [VerfasserIn]   i
 Umansky, Viktor [VerfasserIn]   i
Titel:Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression
Mitwirkende:Nagibin, Vasyl   i
Verf.angabe:Viktor Fleming, Xiaoying Hu, Rebekka Weber, Vasyl Nagibin, Christopher Groth, Peter Altevogt, Jochen Utikal and Viktor Umansky
E-Jahr:2018
Jahr:02 March 2018
Umfang:1 S.
Fussnoten:Gesehen am 15.04.2020
Titel Quelle:Enthalten in: Frontiers in immunology
Ort Quelle:Lausanne : Frontiers Media, 2010
Jahr Quelle:2018
Band/Heft Quelle:9(2018), Artikel-ID 398
ISSN Quelle:1664-3224
Abstract:The immune system has many sophisticated mechanisms to balance an extensive immune response. Distinct immunosuppressive cells could protect from excessive tissue damage and autoimmune disorders. Tumor cells take an advantage of those immunosuppressive mechanisms and establish a strongly immunosuppressive tumor microenvironment (TME), which inhibits antitumor immune responses, supporting the disease progression. Myeloid-derived suppressor cells (MDSC) play a crucial role in this immunosuppressive TME. Those cells represent a heterogeneous population of immature myeloid cells with a strong immunosuppressive potential. They inhibit an antitumor reactivity of T cells and NK cells. Furthermore, they promote angiogenesis, establish pre-metastatic niches, and recruit other immunosuppressive cells such as regulatory T cells. Accumulating evidences demonstrated that the enrichment and activation of MDSC correlated with tumor progression, recurrence, and negative clinical outcome. In the last few years, various preclinical studies and clinical trials targeting MDSC showed promising results. In this review, we discuss different therapeutic approaches on MDSC targeting to overcome immunosuppressive TME and enhance the efficiency of current tumor immunotherapies.
DOI:doi:10.3389/fimmu.2018.00398
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://dx.doi.org/10.3389/fimmu.2018.00398
 DOI: https://doi.org/10.3389/fimmu.2018.00398
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:Animals
 cancer immunotherapy
 Clinical Trials as Topic
 Humans
 Immune Tolerance
 immunosuppression
 Immunotherapy
 Killer Cells, Natural
 Lymphocyte Activation
 myeloid-derived suppressor cells
 Myeloid-Derived Suppressor Cells
 Neoplasms
 T-Lymphocytes
 therapeutic targeting
 Tumor Escape
 tumor microenvironment
 Tumor Microenvironment
K10plus-PPN:1694609944
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68564646   QR-Code
zum Seitenanfang